- Friday, November 3, 2023
8:00 AM – 8:15 AM ET
Welcome and Introduction
8:00 AM – 8:15 AM ET
Welcome and Introduction
8:15 AM – 8:50 AM ET
Session 15: Special Topics in HR+ Breast Cancer
8:15 AM – 8:50 AM ET
Session 15: Special Topics in HR+ Breast CancerPresenter: – Winship Cancer Institute at Emory University
Kevin Kalinsky, MD, MS (he/him/his) – Winship Cancer Institute at Emory University ### 1538154###Presenter###Director, Glenn Family Breast Center###Winship Cancer Institute at Emory University###Presenter: – Winship Cancer Institute at Emory University
### he/him/his8:50 AM – 9:00 AM ET
Live Q&A
8:50 AM – 9:00 AM ET
Live Q&APresenter: – Winship Cancer Institute at Emory University
Kevin Kalinsky, MD, MS (he/him/his) – Winship Cancer Institute at Emory University ### 1538154###Presenter###Director, Glenn Family Breast Center###Winship Cancer Institute at Emory University###Presenter: – Winship Cancer Institute at Emory University
### he/him/his9:00 AM – 9:15 AM ET
Break
9:00 AM – 9:15 AM ET
Break
9:15 AM – 10:00 AM ET
Session 16: ER-Positive Targeted Therapy: PI3, AKT, mTOR, etc
9:15 AM – 10:00 AM ET
Session 16: ER-Positive Targeted Therapy: PI3, AKT, mTOR, etcPresenter: – Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology
Joyce O'Shaughnessy, MD – Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology ### 1879169###Presenter###Medical Oncologist###Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology###Presenter: – Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology
### 10:00 AM – 10:15 AM ET
Break
10:00 AM – 10:15 AM ET
Break
10:15 AM – 11:15 AM ET
Non-CME Innovation Theater
10:15 AM – 11:15 AM ET
Non-CME Innovation Theater
11:15 AM – 11:30 AM ET
Break
11:15 AM – 11:30 AM ET
Break
11:30 AM – 12:05 PM ET
Session 17: HER2-Positive Metastatic Breast Cancer: Where are We Headed?
11:30 AM – 12:05 PM ET
Session 17: HER2-Positive Metastatic Breast Cancer: Where are We Headed?Presenter: – University of California, Los Angeles
Sara Hurvitz, MD – University of California, Los Angeles ### 1186881###Presenter###Professor of Medicine###University of California, Los Angeles###Presenter: – University of California, Los Angeles
### 11:30 AM – 12:15 PM ET
Session 17: HER2-Positive Metastatic Breast Cancer: Where are We Headed?
12:05 PM – 12:15 PM ET
Live Q&AModerator: – Sarah Cannon Research Institute (SCRI)
Presenter: – University of California, Los Angeles
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Moderator###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###Moderator: – Sarah Cannon Research Institute (SCRI)
### @@@ Sara Hurvitz, MD – University of California, Los Angeles ### 1186881###Presenter###Professor of Medicine###University of California, Los Angeles###Presenter: – University of California, Los Angeles
### 12:15 PM – 12:30 PM ET
Break
12:15 PM – 12:30 PM ET
Break
12:30 PM – 1:05 PM ET
Session 18: Immunotherapy for Breast Cancer
12:30 PM – 1:05 PM ET
Session 18: Immunotherapy for Breast CancerPresenter: – International Breast Cancer Center , IBCC
Javier Cortes, MD, PhD – International Breast Cancer Center , IBCC ### 1186877###Presenter###Head###International Breast Cancer Center , IBCC###Presenter: – International Breast Cancer Center , IBCC
### 1:05 PM – 1:15 PM ET
Live Q&A
1:05 PM – 1:15 PM ET
Live Q&AModerator: – Sarah Cannon Research Institute (SCRI)
Presenter: – International Breast Cancer Center , IBCC
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Moderator###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###Moderator: – Sarah Cannon Research Institute (SCRI)
### @@@ Javier Cortes, MD, PhD – International Breast Cancer Center , IBCC ### 1186877###Presenter###Head###International Breast Cancer Center , IBCC###Presenter: – International Breast Cancer Center , IBCC
### 1:15 PM – 1:30 PM ET
Break
1:15 PM – 1:30 PM ET
Break
1:30 PM – 2:05 PM ET
Session 19: PARP Inhibitors and Beyond in Breast Cancer Treatment
1:30 PM – 2:05 PM ET
Session 19: PARP Inhibitors and Beyond in Breast Cancer Treatment
Hope S. Rugo, MD, FASCO – Helen Diller Family Comprehensive Cancer Center; University of California, San Francisco ### 1186884###Invited Speaker###Professor of Medicine; Director, Breast Oncology and Clinical Trials Education###Helen Diller Family Comprehensive Cancer Center; University of California, San Francisco###Invited Speaker: – Helen Diller Family Comprehensive Cancer Center; University of California, San Francisco
### @@@ Joyce O'Shaughnessy, MD – Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology ### 1879169###Invited Speaker###Medical Oncologist###Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology###Invited Speaker: – Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology
### 2:05 PM – 2:15 PM ET
Live Q&A
2:05 PM – 2:15 PM ET
Live Q&AModerator: – Sarah Cannon Research Institute (SCRI)
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Moderator###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###Moderator: – Sarah Cannon Research Institute (SCRI)
### @@@ Tiffany Traina ### 2144178###Invited Speaker#########Invited Speaker:
### 2:15 PM – 2:30 PM ET
Break
2:15 PM – 2:30 PM ET
Break
2:30 PM – 3:15 PM ET
Session 20: Novel Endocrine Backbones
2:30 PM – 3:15 PM ET
Session 20: Novel Endocrine BackbonesPresenter: – Sarah Cannon Research Institute (SCRI)
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Presenter###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###Presenter: – Sarah Cannon Research Institute (SCRI)
### 3:15 PM – 3:30 PM ET
Break
3:15 PM – 3:30 PM ET
Break
3:30 PM – 4:05 PM ET
Session 21: HER2-Low Breast Cancer: Limits of Testing and Where To Go From Here
3:30 PM – 4:05 PM ET
Session 21: HER2-Low Breast Cancer: Limits of Testing and Where To Go From HerePresenter: – Dana-Farber Cancer Institute, Harvard Medical School
Paolo Tarantino, MD (he/him/his) – Dana-Farber Cancer Institute, Harvard Medical School ### 1928334###Presenter###Advanced Research Fellow###Dana-Farber Cancer Institute, Harvard Medical School###Presenter: – Dana-Farber Cancer Institute, Harvard Medical School
### he/him/his4:05 PM – 4:15 PM ET
Live Q&A
4:05 PM – 4:15 PM ET
Live Q&AModerator: – Sarah Cannon Research Institute (SCRI)
Presenter: – Dana-Farber Cancer Institute, Harvard Medical School
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Moderator###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###Moderator: – Sarah Cannon Research Institute (SCRI)
### @@@ Paolo Tarantino, MD (he/him/his) – Dana-Farber Cancer Institute, Harvard Medical School ### 1928334###Presenter###Advanced Research Fellow###Dana-Farber Cancer Institute, Harvard Medical School###Presenter: – Dana-Farber Cancer Institute, Harvard Medical School
### he/him/his
